242 related articles for article (PubMed ID: 15252577)
21. Prion protein fate governed by metal binding.
Tsenkova RN; Iordanova IK; Toyoda K; Brown DR
Biochem Biophys Res Commun; 2004 Dec; 325(3):1005-12. PubMed ID: 15541389
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation.
Sola Vigo F; Kedikian G; Heredia L; Heredia F; Añel AD; Rosa AL; Lorenzo A
Neurobiol Aging; 2009 Sep; 30(9):1379-92. PubMed ID: 18187234
[TBL] [Abstract][Full Text] [Related]
23. Pathogenic mechanisms in Alzheimer's disease.
Pastorino L; Lu KP
Eur J Pharmacol; 2006 Sep; 545(1):29-38. PubMed ID: 16904664
[TBL] [Abstract][Full Text] [Related]
24. Fibrillar prion peptide PrP(106-126) treatment induces Dab1 phosphorylation and impairs APP processing and Abeta production in cortical neurons.
Gavín R; Ureña J; Rangel A; Pastrana MA; Requena JR; Soriano E; Aguzzi A; Del Río JA
Neurobiol Dis; 2008 May; 30(2):243-54. PubMed ID: 18374587
[TBL] [Abstract][Full Text] [Related]
25. Doppel: more rival than double to prion.
Qin K; O'Donnell M; Zhao RY
Neuroscience; 2006 Aug; 141(1):1-8. PubMed ID: 16781817
[TBL] [Abstract][Full Text] [Related]
26. Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein.
Heredia L; Lin R; Vigo FS; Kedikian G; Busciglio J; Lorenzo A
Neurobiol Dis; 2004 Aug; 16(3):617-29. PubMed ID: 15262274
[TBL] [Abstract][Full Text] [Related]
27. Redox metals and oxidative abnormalities in human prion diseases.
Petersen RB; Siedlak SL; Lee HG; Kim YS; Nunomura A; Tagliavini F; Ghetti B; Cras P; Moreira PI; Castellani RJ; Guentchev M; Budka H; Ironside JW; Gambetti P; Smith MA; Perry G
Acta Neuropathol; 2005 Sep; 110(3):232-8. PubMed ID: 16096758
[TBL] [Abstract][Full Text] [Related]
28. APP, NGF & the 'Sunday-driver' in a Trolley on the Road.
Heese K; Inoue N; Nagai Y; Sawada T
Restor Neurol Neurosci; 2004; 22(2):131-6. PubMed ID: 15272147
[TBL] [Abstract][Full Text] [Related]
29. Aggregation/fibrillogenesis of recombinant human prion protein and Gerstmann-Sträussler-Scheinker disease peptides in the presence of metal ions.
Ricchelli F; Buggio R; Drago D; Salmona M; Forloni G; Negro A; Tognon G; Zatta P
Biochemistry; 2006 May; 45(21):6724-32. PubMed ID: 16716083
[TBL] [Abstract][Full Text] [Related]
30. Trafficking and degradation pathways in pathogenic conversion of prions and prion-like proteins in neurodegenerative diseases.
Victoria GS; Zurzolo C
Virus Res; 2015 Sep; 207():146-54. PubMed ID: 25645281
[TBL] [Abstract][Full Text] [Related]
31. Slow virus disease: deciphering conflicting data on the transmissible spongiform encephalopathies (TSE) also called prion diseases.
Bastian FO; Fermin CD
Microsc Res Tech; 2005 Nov; 68(3-4):239-46. PubMed ID: 16276518
[TBL] [Abstract][Full Text] [Related]
32. [Conformationally altered proteins cause neurodegenerative diseases].
Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L
Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development.
Kerr ML; Small DH
J Neurosci Res; 2005 Apr; 80(2):151-9. PubMed ID: 15672415
[TBL] [Abstract][Full Text] [Related]
34. The effects of prion protein expression on metal metabolism.
Kralovicova S; Fontaine SN; Alderton A; Alderman J; Ragnarsdottir KV; Collins SJ; Brown DR
Mol Cell Neurosci; 2009 Jun; 41(2):135-47. PubMed ID: 19233277
[TBL] [Abstract][Full Text] [Related]
35. Tubulovesicular structures are a consistent (and unexplained) finding in the brains of humans with prion diseases.
Liberski PP; Sikorska B; Hauw JJ; Kopp N; Streichenberger N; Giraud P; Budka H; Boellaard JW; Brown P
Virus Res; 2008 Mar; 132(1-2):226-8. PubMed ID: 18164506
[TBL] [Abstract][Full Text] [Related]
36. Copper reduction by the octapeptide repeat region of prion protein: pH dependence and implications in cellular copper uptake.
Miura T; Sasaki S; Toyama A; Takeuchi H
Biochemistry; 2005 Jun; 44(24):8712-20. PubMed ID: 15952778
[TBL] [Abstract][Full Text] [Related]
37. Prions and prion diseases: fundamentals and mechanistic details.
Ryou C
J Microbiol Biotechnol; 2007 Jul; 17(7):1059-70. PubMed ID: 18051314
[TBL] [Abstract][Full Text] [Related]
38. BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration.
Yoon SY; Choi JE; Yoon JH; Huh JW; Kim DH
Neurobiol Dis; 2006 May; 22(2):435-44. PubMed ID: 16480887
[TBL] [Abstract][Full Text] [Related]
39. Intriguing nucleic-acid-binding features of mammalian prion protein.
Silva JL; Lima LM; Foguel D; Cordeiro Y
Trends Biochem Sci; 2008 Mar; 33(3):132-40. PubMed ID: 18243708
[TBL] [Abstract][Full Text] [Related]
40. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
